Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Compass Therapeutics Inc. logo — We are developing next-generation antibodies into transforma...

Compass Therapeutics Inc.

We are developing next-generation antibodies into transformative cancer therapies that improve patients’ lives.

Founded 2014 United States Boston, United States 57 employees IPO Total: $500.96M Biopharma, Biotechnology +1

General Information

Company Name Compass Therapeutics Inc.
Founded Year 2014
Location United States Boston, United States +1
Employees 57
Industries Biopharma, Biotechnology, Health and Wellness
Funding Stage IPO
Social

Get notified when Compass Therapeutics Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Compass Therapeutics Inc.

Compass Therapeutics Inc. is a clinical-stage, oncology-focused biopharmaceutical company that aims to develop next-generation antibodies into transformative cancer therapies, ultimately improving patients’ lives. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. Their pipeline of novel product candidates is designed to target critical biological pathways required for an effective anti-tumor response, including modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics plans to advance its product candidates through clinical development as standalone therapies and in combination with proprietary pipeline antibodies. The company has received a recent $80.00M post-IPO equity investment at 02 November 2022 from a group of prominent investors including OrbiMed, Vivo Capital, Adage Capital Management, Enavate Sciences, Janus Handerson, Monashee Investment Management, DAFNA Capital Management, LLC, and Braidwell. To learn more about Compass Therapeutics Inc., visit www.compasstherapeutics.com.

Taxonomy: biopharmaceutical company, oncology-focused, antibody-based therapeutics, cancer therapies, angiogenesis, tumor growth, immunotherapy, clinical-stage, proprietary pipeline antibodies, immunosuppressive mechanisms, combination therapies, microvasculature modulation, effector cells, immune surveillance, Boston

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 Dec 2025
Post Ipo Equity •••••• - 01 Aug 2025
Private Placement Vc •••••• 8
Investor Investor Investor Investor Investor Investor Investor Investor
01 Nov 2022
Post Ipo Equity •••••• - 01 Nov 2021
IPO •••••• - 01 Apr 2021

View All 11 Funding Rounds

Compass Therapeutics Inc. Alternatives & Competitors

Compass Therapeutics Inc. vs
iTeos Therapeutics
iTeos Therapeutics United States

Cancer Immunotherapies by Design

Post Ipo Equity
186 employees
Biotechnology, Health Care
Compare Compass Therapeutics Inc. vs iTeos Therapeutics
Compass Therapeutics Inc. vs
Nammi Therapeutics, Inc.
Nammi Therapeutics, Inc. United States

Nammi aims to improve cancer care by co-delivering combinations of immunotherapy to tumor using prop...

Series B
8 employees
Biotechnology, Health and Wellness
Compare Compass Therapeutics Inc. vs Nammi Therapeutics, Inc.
Compass Therapeutics Inc. vs
Nonagen Therapeutics Corporation
Nonagen Therapeutics Corporation United States

Our mission is to discover and develop breakthrough therapeutics for human diseases

2 employees
Biotechnology
Also compare with: Compass Therapeutics Inc. vs KSQ Therapeutics, Inc. KSQ Therapeutics, Inc.

FAQ About Compass Therapeutics Inc.

We are developing next-generation antibodies into transformative cancer therapies that improve patients’ lives.
Compass Therapeutics Inc. was founded in 2014.
Compass Therapeutics Inc. is headquartered in Boston, United States.
Compass Therapeutics Inc. operates in the following industries: Biopharma, Biotechnology, Health and Wellness.
Compass Therapeutics Inc. has approximately 57 employees.
Compass Therapeutics Inc. has completed 11 funding rounds, raising a total of $500.96M. The latest funding stage is IPO.
Top alternatives and competitors to Compass Therapeutics Inc. include iTeos Therapeutics, Nammi Therapeutics, Inc., Nonagen Therapeutics Corporation, KSQ Therapeutics, Inc., ImmunoCellular Therapeutics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Compass Therapeutics Inc. and iTeos Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Compass Therapeutics Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy